Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

被引：7
|
作者：
Marder, S. [1 ]
Laszlovszky, I. [2 ]
Szalai, E. [2 ]
Szatmari, B. [2 ]
Harsanyi, J. [2 ]
Barabassy, A. [2 ]
Debelle, M. [2 ]
Durgam, S. [3 ]
Bitter, I. [4 ]
Nemeth, G. [2 ]
机构：
[1] Univ Calif Los Angeles, Semel Inst, Sect Psychosis, Los Angeles, CA USA
[2] Gedeon Richter Plc, Med Div, Budapest, Hungary
[3] Forest Res Inst, Clin Dev, Jersey City, NJ USA
[4] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31595-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.036
引用
收藏
页码：S550 / S550
页数：1
相关论文
共 50 条
  • [21] Amisulpride:: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia
    Möller, HJ
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2001, 251 (05) : 217 - 224
  • [22] Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia
    Hans-Jürgen Möller
    European Archives of Psychiatry and Clinical Neuroscience, 2001, 251 : 217 - 224
  • [23] The effect of cariprazine on agitation and hostility in patients with schizophrenia: post-hoc analysis
    Sebe, B.
    Barabassy, A.
    Acsai, K.
    Laszlovszky, I.
    Dombi, Z. B.
    Vass, G.
    Szatmari, B.
    Patel, M.
    Earley, W.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S327 - S328
  • [24] Diagnosis of predominant negative symptoms: Post-hoc analyses of a phase 3 clinical trial with cariprazine monotherapy and risperidone
    Laszlovszky, I.
    Barabassy, A.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2017, 41 : S270 - S270
  • [25] THE EFFECT OF LURASIDONE ON PANSS MARDER 5 FACTORS AND INDIVIDUAL ITEMS IN PATIENTS WITH ACUTE SCHIZOPHRENIA: A POST- HOC ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIAL (JEWEL STUDY)
    Takai, Kentaro
    Miura, Itaru
    Toya, Shunji
    Sano, Fumiya
    Iyo, Masaomi
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : I162 - I163
  • [26] Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms - Results from an exploratory re-analysis
    Hansbauer, Maximilian
    Wobrock, Thomas
    Kunze, Birgit
    Langguth, Berthold
    Landgrebe, Michael
    Eichhammer, Peter
    Frank, Elmar
    Cordes, Joachim
    Woelwer, Wolfgang
    Winterer, Georg
    Gaebel, Wolfgang
    Hajak, Goeran
    Ohmann, Christian
    Verde, Pablo E.
    Rietschel, Marcella
    Ahmed, Raees
    Honer, William G.
    Malchow, Berend
    Strube, Wolfgang
    Schneider-Axmann, Thomas
    Falkai, Peter
    Hasan, Alkomiet
    PSYCHIATRY RESEARCH, 2018, 263 : 22 - 29
  • [27] Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
    Vasiliu, Octavian
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [28] The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
    McIntyre, Roger S.
    Daniel, David G.
    Vieta, Eduard
    Laszlovszky, Istvan
    Goetghebeur, Pascal J.
    Earley, Willie R.
    Patel, Mehul D.
    CNS SPECTRUMS, 2023, 28 (03) : 319 - 330
  • [29] Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone
    Nemeth, Bertalan
    Molnar, Anett
    Akehurst, Ron
    Horvath, Margit
    Koczian, Kristof
    Nemeth, Gyorgy
    Gotze, Arpad
    Voko, Zoltan
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (08) : 639 - 648
  • [30] Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial
    Debelle, M.
    Nemeth, G.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Barabassy, A.
    Laszlovszky, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S510 - S510
12345